The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

Amgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

CytomX Therapeutics, a Bay Area biotech firm with lucrative and high-profile partnerships in the industry, is laying off 40% ...

New Delhi, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global pharma & biotech CRM software market was valued at US$ 7.21 billion IN 2024 and is projected to reach US$ 20.0 by 2033 at a CAGR of 15.2% during ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...